Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer
Conditions
Uterine Cervical Cancer
Conditions: official terms
Uterine Cervical Neoplasms
Conditions: Keywords
Advanced uterine cervical cancer
Study Type
Interventional
Study Phase
Phase 2
Study Design
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: albumin-bound paclitaxel plus nedaplatin
Type: Drug
Overall Status
Recruiting
Summary
Using albumin-bound paclitaxel and nedaplatin in the advanced or recurrent metastasis cervical cancer, to evaluate the efficacy and toxic reaction.
Detailed Description
Albumin-bound paclitaxel is a novel, solvent-free, albumin-bound nanoparticle form of paclitaxel designed to avoid problems associated with solvents used in Taxol. And albumin-bound paclitaxel was characterized with high tolerated doses with greater efficacy, and with greater concentration in tumor tissue compared with normal tissues. This is a single center, non-randomized, open-label Phase II clinical study to investigate the efficacy and tolerability of albumin-bound paclitaxel plus nedaplatin in patients with advanced, recurrent metastatic cervical cancer. About 30 patients will receive 175-200 mg/m2 albumin-bound paclitaxel, d 1 combined with 80- 100 mg/m2 nedaplatin, d 2, every 3 weeks. At least 2 cycles will be completed for each patient, for whom responded to the treatment, 4-6 cycles will be completed.
Criteria for eligibility
Healthy Volunteers: Accepts Healthy Volunteers
Maximum Age: 70 Years
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

- Cervical cancer, advanced or recurrent metastasis

- Measurable and assessible tumor lesions

- Used ordinary paclitaxel or platinum drugs, more than 28 days

- Aged 18-70

- KPS score> 60 points, expected to survive more than 3 months

- Normal bone marrow function

- The function of liver and kidney had no obvious damage

- Normal function of vital organs

- No brain metastases

- Patients or their agents to sign informed consent

- Compliance, and can be followed up regularly

Exclusion Criteria:

- Brain metastases

- Serious complications

- Acute inflammatory response

- Combined with other tumor

- Pregnancy or breast-feeding women

- Vertebral metastasis with nerve compression symptoms

- Large volume of pleural effusion, pericardial effusion

- Other malignancy within five years

- Drug allergy

- Other chemotherapy contraindications

- The possibility of pregnancy, and not willing to contraception

- No measurement of lesion

- Mental illness which is difficult to control
Location
Chinese Academy of Medical Sciences, Cancer Hospital, Gynecologic Oncology
Beijing, China
Status: Recruiting
Contact: Rong Zhang - 008613911982343 - super0078888@sina.com
Start Date
November 2011
Completion Date
December 2016
Sponsors
Chinese Academy of Medical Sciences
Source
Chinese Academy of Medical Sciences
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page